Skip to content
naulon

Not checkedNot checked for notices yet.

An epithelial-to-mesenchymal transition induced extracellular vesicle prognostic signature in non-small cell lung cancer

Richard J. Lobb, Kekoolani S. Visan, Li-Ying Wu and 12 more

Communications Biology · 2023

doi:10.1038/s42003-022-04350-4 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Despite significant therapeutic advances, lung cancer remains the leading cause of cancer-related death worldwide 1 . Non-small cell lung cancer (NSCLC) patients have a very poor overall five-year survival rate of only 10–20%. Currently, TNM staging is the gold standard for predicting overall survival and selecting optimal initial treatment options for NSCLC patients, including those with curable stages of disease. However, many patients with locoregionally-confined NSCLC relapse and die despite curative-intent interventions, indicating a need for intensified, individualised therapies. Epithelial-to-mesenchymal transition (EMT), the phenotypic depolarisation of epithelial cells to elongated, mesenchymal cells, is associated with metastatic and treatment-refractive cancer. We demonstrate here that EMT-induced protein changes in small extracellular vesicles are detectable in NSCLC patients and have prognostic significance. Overall, this work describes a novel prognostic biomarker signature that identifies potentially-curable NSCLC patients at risk of developing metastatic NSCLC, thereby enabling implementation of personalised treatment decisions.

Abstract licence: CC BY-NC-ND

References48

    40 more references, whose wording the paper’s licence keeps private.

    All 48 references

    Cited by papers we hold1

    Reads

    Read by people on this page

    None yet.

    Checked or read by AI through naulon

    None yet.

    A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

    Are you an author?

    Is this your paper?

    Claim it to add your note and be paid when agents cite it. Free.